Blog
RSS FeedPosted by Michael Wonder on 02 Apr 2023
Survey on patients' access to medicines for the treatment of rare health conditions
31 March 2023 - The TLV has submitted an interim report to the government for the task of proposing how ...
Posted by Michael Wonder on 28 Mar 2023
Clarification on the subsidy limitation for drugs for diabetes
28 March 2023 - The TLV has clarified the subsidy limitation for all GLP-1 receptor agonists. ...
Posted by Michael Wonder on 27 Mar 2023
Final reconciliation of savings from side agreements for the full year 2022
28 March 2023 - The TLV has presented the Government with the final reconciliation of the outcome of savings from ...
Posted by Michael Wonder on 25 Mar 2023
TLV is preparing for an increase in ceiling prices
17 March 2023 - In order to ensure continued good access to medicines for patients, TLV started in the autumn of ...
Posted by Michael Wonder on 16 Feb 2023
Health economic assessment of Kimmtrak in disseminated ocular melanoma
16 February 2023 - The assessment applies to Kimmtrak as the sole treatment for adult patients with melanoma in the ...
Posted by Michael Wonder on 31 Jan 2023
International price comparison of medicines (2022)
31 January 2023 - The price of prescription drugs in Sweden has fallen compared to other countries since 2014 and is ...
Posted by Michael Wonder on 21 Nov 2022
TLV subsidises anti-viral treatment of COVID-19 to risk groups
21 November 2022 - Paxlovid, which treats patients who are at risk of becoming seriously ill from COVID-19, will be ...
Posted by Michael Wonder on 21 Nov 2022
TLV subsidises drugs against cystic fibrosis
18 November 2022 - The Dental and Pharmaceutical Benefits Agency, TLV, has decided that the drugs Kaftrio, Kalydeco and Symkevi, ...
Posted by Michael Wonder on 05 Oct 2022
Continued development of the national health data registers leads to better follow-up of medicines
3 October 2022 - The Dental and Pharmaceutical Benefits Agency (TLV) is today handing over a report to the government on ...
Posted by Michael Wonder on 11 Sep 2022
Exits from pharmaceutical benefits on 1 October 2022
8 September 2022 - Below is a compilation of the medicines in different packaging sizes which, at the companies' own ...
Posted by Michael Wonder on 04 Jul 2022
TLV reconsiders Orkambi's subsidy
4 July 2022 - TLV has started a reconsideration of the drug Orkambi in light of the fact that the ...
Posted by Michael Wonder on 27 Jun 2022
TLV receives assignments for medicines for rare diseases
27 June 2022 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to analyse and make ...
Posted by Michael Wonder on 27 Jun 2022
TLV receives a new assignment on precision medicine and ATMP
27 June 2022 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to continue the work ...
Posted by Michael Wonder on 20 Jun 2022
Zeposia is included in the high-cost protection with limitation
17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022. ...
Posted by Michael Wonder on 16 Jun 2022
Subsidy for medicine for Duchenne muscular dystrophy expires
16 June 2022 - The TLV has decided that Translarna, which is subsidised for patients with Duchenne muscular dystrophy, will not ...